Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study)
This Paper With 6 Page And PDF Format Ready To Download
- Certificate
- I'm the author of the paper
Export:
Document National Code:
Index date: 23 September 2019
Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study) abstract
Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study) Keywords:
Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study) authors
Thromboses Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran
Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Thromboses Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran
مراجع و منابع این Paper: